• 1
    Howe HL, Wu X, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2003, featuring cancer among U.S. Hispanic/Latino populations. Cancer. 2006; 107: 1711-1742.
  • 2
    Bailar JC3rd, Smith EM. Progress against cancer? N Engl J Med. 1986; 314: 1226-1232.
  • 3
    Morrell S, Kerr C, Driscoll T, Taylor R, Salkeld G, Corbett S. Best estimate of the magnitude of mortality due to occupational exposure to hazardous substances. Occup Environ Med. 1998; 55: 634-641.
  • 4
    Ries LAG, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, Md: National Cancer Institute; based on the November 2006 SEER data submission, posted to the SEER website 2007. Available at: Accessed on December 15, 2009.
  • 5
    Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981; 66: 1191-1308.
  • 6
    Peto R. Smoking and death: the past 40 years and the next 40. BMJ. 1994; 309: 937-939.
  • 7
    Dinse GE, Umbach DM, Sasco AJ, Hoel DG, Davis DL. Unexplained increases in cancer incidence in the United States from 1975 to 1994: possible sentinel health indicators? Annu Rev Public Health. 1999; 20: 173-209.
  • 8
    Surveillance Epidemiology and End Results (SEER) Program. SEER 1973-2004 Public Use Data. SEER*Stat Database: Incidence-SEER 9 Registries, November 2006 submission (1973-2004). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007, based on the November 2006 submission. Available at: http://www.seer.cancer. gov. Accessed on December 15, 2009.
  • 9
    Surveillance Epidemiology and End Results (SEER) Program. SEER 1973-2004 Public Use Data (www.seer.cancer. gov). SEER*Stat Database: Mortality-All COD, Aggregated With State, Total U.S. (1969-2004). Bethesda, Md: National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch; released April 2007 (underlying mortality data provided by NCHS). Available at: Accessed on December 15, 2009.
  • 10
    Midthune DN, Fay MP, Clegg LX, Feuer EJ. Modeling reporting delays and reporting corrections in cancer registry data. J Am Stat Assoc. 2005; 100: 61-70.
  • 11
    U.S. Department of Health and Human Services.Cancer Query Systems: Delay-Adjusted SEER Incidence Rates, vol 2007. Bethesda, Md: National Cancer Institute, SEER Program; 2006.
  • 12
    Clegg LX, Feuer EJ, Midthune DN, Fay MP, Hankey BF. Impact of reporting delay and reporting error on cancer incidence rates and trends. J Natl Cancer Inst. 2002; 94: 1537-1545.
  • 13
    IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Tobacco smoke and involuntary smoking. IARC Monogr Eval Carcinog Risks Hum. 2004; 83: 1/1438.
  • 14
    English DR, Holman CDJ, Milne E, Winter MG, Hulse GK, Codde JP. The Quantification of Drug Caused Morbidity and Mortality in Australia, Commonwealth Department of Human Services and Health. Canberra, Australian Capital Territory, Australia: Australian Government Publishing Service; 1995.
  • 15
    Centers for Disease Control and Prevention. Annual smoking-attributable mortality, years of potential life lost, and productivity loses-United States, 1997-2001. MMWR Morb Mortal Wkly Rep. 2005; 54: 625-628.
  • 16
    Holford TR. The estimation of age, period and cohort effects for vital rates. Biometrics. 1983; 39: 311-324.
  • 17
    Breslow NE. Extra-Poisson variation in log-linear models. Appl Stat. 1984; 33: 38/44.
  • 18
    Centers for Disease Control and Prevention. Cigarette smoking among adults—United States, 2004. MMWR Morb Mortal Wkly Rep. 2005; 54: 1121-1124.
  • 19
    Axelson O, Davis DL, Forestiere F, Schneiderman M, Wagener D. Lung cancer not attributable to smoking. Ann N Y Acad Sci. 1990; 609: 165-176; discussion 176-178.
  • 20
    National Cancer Institute.Cancer Trend Progress Report-2005 Update, vol 2007. Bethesda, Md: National Cancer Institute; 2005.
  • 21
    Breen N, Cronin K, Meissner HI, et al. Reported drop in mammography: is this cause for concern? Cancer. 2007; 109: 2405-2409.
  • 22
    Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003; 97: 1528-1540.
  • 23
    Berry DA, Cronin KA, Plevritis SK, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005; 353: 1784-1792.
  • 24
    Clarke CA, Glaser SL, Uratsu CS, Selby JV, Kushi LH, Herrinton LJ. Recent declines in hormone therapy utilization and breast cancer incidence: clinical and population-based evidence. J Clin Oncol. 2006; 24: e49-e50.
  • 25
    Clemons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med. 2001; 344: 276-285.
  • 26
    Davis DL. The Secret History of the War on Cancer. New York, NY: Basic Books; 2007.
  • 27
    Sweeney C, Baumgartner KB, Byers T, et al. Reproductive history in relation to breast cancer risk among Hispanic and non-Hispanic white women. Cancer Causes Control. 2008; 19: 391/401.
  • 28
    Butler LM, Gold EB, Greendale GA, et al. Menstrual and reproductive factors in relation to mammographic density: the Study of Women's Health Across the Nation (SWAN). Breast Cancer Res Treat. 2008; 112: 165/174.
  • 29
    Chu KC, Tarone RE, Freeman HP. Trends in prostate cancer mortality among black men and white men in the United States. Cancer. 2003; 97: 1507-1516.
  • 30
    Etzioni R, Legler JM, Feuer EJ, Merrill RM, Cronin KA, Hankey BF. Cancer surveillance series: interpreting trends in prostate cancer—part III: quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. J Natl Cancer Inst. 1999; 91: 1033-1039.
  • 31
    Jones BA, Liu WL, Araujo AB, et al. Explaining the race difference in prostate cancer stage at diagnosis. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2825-2834.
  • 32
    Espey DK, Wu XC, Swan J, et al. Annual report to the nation on the status of cancer, 1975-2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007; 110: 2119-2152.
  • 33
    Wong MD, Ettner SL, Boscardin WJ, Shapiro MF. The contribution of cancer incidence, stage at diagnosis and survival to racial differences in years of life expectancy. J Gen Intern Med. 2009; 24: 475-481.
  • 34
    Lynge E, Anttila A, Hemminki K. Organic solvents and cancer. Cancer Causes Control. 1997; 8: 406-419.
  • 35
    Merhi M, Raynal H, Cahuzac E, Vinson F, Cravedi JP, Gamet-Payrastre L. Occupational exposure to pesticides and risk of hematopoietic cancers: meta-analysis of case-control studies. Cancer Causes Control. 2007; 18: 1209-1226.
  • 36
    McGregor D. Industrial chemicals and human cancer. Biotherapy. 1998; 11: 181-188.
  • 37
    Blair A, Steenland K, Shy C, O'Berg M, Halperin W, Thomas T. Control of smoking in occupational epidemiologic studies: methods and needs. Am J Ind Med. 1988; 13: 3-4.
  • 38
    Donovan M, Tiwary CM, Axelrod D, et al. Personal care products that contain estrogens or xenoestrogens may increase breast cancer risk. Med Hypotheses. 2007; 68: 756-766.
  • 39
    Reeves GK, Pirie K, Beral V, Green J, Spencer E, Bull D. Cancer incidence and mortality in relation to body mass index in the Million Women Study: cohort study [serial online]. BMJ. 2007; 335: 1134.
  • 40
    Rapp K, Schroeder J, Klenk J, et al. Obesity and incidence of cancer: a large cohort study of over 145,000 adults in Austria. Br J Cancer. 2005; 93: 1062-1067.
  • 41
    Brandes LJ. Hormetic effects of hormones, antihormones, and antidepressants on cancer cell growth in culture: in vivo correlates. Crit Rev Toxicol. 2005; 35: 587-592.
  • 42
    Nelson RA, Levine AM, Marks G, Bernstein L. Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma. Br J Cancer. 1997; 76: 1532-1537.
  • 43
    Toossi M. A century of change: the U.S. labor force from 1950 to 2050. Monthly Labor Rev. 2002; 125: 15-28.
  • 44
    U.S. Office of Personnel Management, Central Personnel Data File (CPDF). Executive Branch (non-Postal) Employment by Gender, Race/National Origin, Disability Status, Veterans Status, Disabled Veterans, 1994-2004, volume 2007. Washington, DC: U.S. Office of Personnel Management, CPDF; 2006.
  • 45
    Zahm SH, Blair A. Occupational cancer among women: where have we been and where are we going? Am J Ind Med. 2003; 44: 565-575.
  • 46
    Ward E. Overview of preventable industrial causes of occupational cancer. Environ Health Perspect. 1995; 103( suppl 8): 197-203.
  • 47
    Straif K, Baan R, Grosse Y, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007; 8: 1065-1066.
  • 48
    Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371: 569-578.
  • 49
    Brenner DJ, Hall EJ. Computed tomography—an increasing source of radiation exposure. N Engl J Med. 2007; 357: 2277-2284.
  • 50
    Amis ESJr, Butler PF, Applegate KE, et al. American College of Radiology white paper on radiation dose in medicine. J Am Coll Radiol. 2007; 4: 272-284.
  • 51
    Hall NE, Rosenman KD. Cancer by industry: analysis of a population-based cancer registry with an emphasis on blue-collar workers. Am J Ind Med. 1991; 19: 145-159.
  • 52
    Montesano R, Hainaut P, Wild CP. Hepatocellular carcinoma: from gene to public health. J Natl Cancer Inst. 1997; 89: 1844-1851.
  • 53
    Erikson C, Salsberg E, Forte G, Bruinooge S, Goldstein M. Future supply and demand for oncologists: challenges to assuring access to oncology services. J Oncol Pract. 2007; 3: 79-86.
  • 54
    Centers for Disease Control and Prevention. Smoking- attributable mortality, years of potential life lost, and productivity losses, United States, 2000-2004. MMWR Morb Mortal Wkly Rep. 2008; 57: 1226-1228.
  • 55
    Mahlck CG, Jonsson H, Lenner P. Pap smear screening and changes in cervical cancer mortality in Sweden. Int J Gynaecol Obstet. 1994; 44: 267-272.
  • 56
    Taylor RJ, Morrell SL, Mamoon HA, Wain GV. Effects of screening on cervical cancer incidence and mortality in New South Wales implied by influences of period of diagnosis and birth cohort. J Epidemiol Commun Health. 2001; 55: 782-788.
  • 57
    Austin H. An epidemic averted through medical screening. J Med Screen. 2005; 12: 1-2.
  • 58
    Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009; 360: 1320-1328.
  • 59
    Andriole GL, Grubb RL, 3rd, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009; 360: 1310-1319.
  • 60
    Mandel JS, Church TR, Ederer F, Bond JH. Colorectal cancer mortality: effectiveness of biennial screening for fecal occult blood. J Natl Cancer Inst. 1999; 91: 434-437.
  • 61
    Kronborg O, Fenger C, Olsen J, Jorgensen OD, Sondergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 1996; 348: 1467-1471.